Bristol-Myers Squibb Company (BMY)

Receivables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	45,006,000	44,935,000	45,187,000	45,848,000	46,159,000	46,738,000	47,144,000	46,960,000	46,385,000	45,468,000	44,384,000	42,810,000	42,518,000	39,395,000	34,862,000	31,006,000	26,145,000	24,173,000	23,857,000	23,288,000
Receivables	US$ in thousands	10,921,000	10,304,000	10,112,000	10,054,000	9,886,000	9,613,000	9,054,000	8,511,000	9,369,000	9,245,000	9,017,000	8,660,000	8,501,000	8,062,000	7,855,000	8,290,000	7,685,000	5,510,000	5,667,000	5,704,000
Receivables turnover		4.12	4.36	4.47	4.56	4.67	4.86	5.21	5.52	4.95	4.92	4.92	4.94	5.00	4.89	4.44	3.74	3.40	4.39	4.21	4.08

December 31, 2023 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $45,006,000K ÷ $10,921,000K
= 4.12

The receivables turnover ratio for Bristol-Myers Squibb Co. has exhibited a declining trend over the past eight quarters, from 5.52 in Q1 2022 to 4.12 in Q4 2023. This indicates that the company is taking longer to collect its accounts receivable. A lower receivables turnover ratio may suggest potential issues with collecting payments from customers, potentially impacting the company's liquidity and cash flow. It is essential for Bristol-Myers Squibb Co. to closely monitor and improve its accounts receivable management to ensure timely collection and overall financial health.